As of Friday close, BridgeBio Pharma Inc.’s (NASDAQ:BBIO) stock was down -$0.26, moving down -1.88 percent to $13.55. The average number of shares traded per day over the past five days has been 3,259,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.51 fall in that time frame. In the last twenty days, the average volume was 5,053,875, while in the previous 50 days, it was 2,939,532.
Since last month, BBIO stock rose 11.07%. Shares of the company fell to $10.57 on 03/02/23, the lowest level in the past month. A 52-week high of $19.94 was reached on 03/07/23 after having rallying from a 52-week low of $4.98. Since the beginning of this year, BBIO’s stock price has risen by 77.82% or $5.93, and marked a new high 19 times. However, the stock has declined by -32.06% since its 52-week high.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
BBIO stock investors should be aware that BridgeBio Pharma Inc. (BBIO) stock had its last reported insider trading activity 15 days ago on Mar 03. Kumar Neil, the CEO and President of the company, disposed of 120,000 shares for $10.96 on Mar 03. It resulted in a $1,315,224 divestment by the insider. STEPHENSON BRIAN C sold 62,692 shares at an average price of $10.96 on Mar 03. The insider now owns 156,837 shares following the transaction. On Feb 17, CEO and President Kumar Neil sold 44,798 shares at $12.70 apiece. The transaction was valued at $569,073.
In the three months ended September 29, BridgeBio Pharma Inc.’s quick ratio stood at 4.50, while its current ratio was 4.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 95.60% percent. Based on annual data, BBIO earned $74.21 million in gross profit and brought in $77.65 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -113.10%. Return on equity (ROE) for the past 12 months was 43.20%.
In BridgeBio Pharma Inc.’s quarter-end financial report for September 29, it reported total debt of $430.99 million against cash and short-term investments of $51.58 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BBIO’s revenue fell -589.3% to $0.34 million during the quarter, while net income inched up to $1.87 million. While analysts expected BridgeBio Pharma Inc. to report -$0.99 quarterly earnings, the actual figure was -$0.93 per share, beating the consensus estimate by 6.10%. During the quarter, the company generated -$127.57 million in EBITDA. The liabilities of BridgeBio Pharma Inc. were 1.87 billion at the end of its most recent quarter ended September 29, and its total debt was $1.72 billion. The value of shareholders’ equity is $151.37 million.
This quick technical analysis looks at BridgeBio Pharma Inc.’s (BBIO) price momentum. With a historical volatility rate of 103.66%, the RSI 9-day stood at 48.78% on 17 March.
With respect to its five-day moving average, the current BridgeBio Pharma Inc. price is down by -3.63% percent or -$0.51. At present, BBIO shares trade +7.20% above its 20-day simple moving average and +29.91% percent above its 100-day simple moving average. However, the stock is currently trading approximately +71.95% above its SMA50 and +98.39% above its SMA200.
Stochastic coefficient K was 35.20% and Stochastic coefficient D was 38.47%, while ATR was 1.37. Given the Stochastic reading of 31.79% for the 14-day period, the RSI (14) reading has been calculated as 52.67%. As of today, the MACD Oscillator reading stands at -1.15, while the 14-day reading stands at -0.14.
Cowen launched its rating on BridgeBio Pharma Inc. (NASDAQ: BBIO) to an Outperform in a note to investors on February 06, 2023. BridgeBio Pharma Inc. (BBIO) has been rated Buy by analysts. According to 0 brokerage firms, BBIO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate BridgeBio Pharma Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $25.50, the current consensus forecast for the stock is $18.00 – $32.00. Based on these forecasts, analysts predict BridgeBio Pharma Inc. (BBIO) will achieve an average price target of $25.63.